Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SODIUM CROMOGLYCATE

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (S01GX) — coverage varies; not interchangeable

  • Ketotifen (Zaditor): not a benefit
  • Olopatadine (Pataday): not a benefit

Cromolyn Eye Drops · DIN 02009277 · 2% · Oph Sol

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cromolyn Eye Drops · DIN 02009277 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1996-10-01 Health Canada: Marketed since 2012-08-21 · brand CROMOLYN EYE DROPS · ATC S01GX01 CROMOGLICIC ACID · form Solution · route Ophthalmic · ingredients CROMOLYN SODIUM 2 % · company Pendopharm division of pharmascience inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Cromolyn Eye Drops: Formulary list price $0.9500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13857 · Verify on the e-Formulary ↗ (DIN 02009277)

Source record
DIN 02009277: Cromolyn Eye Drops Raw flags: sec3=Y Item: 523600019; group id 640; item number 1613; lccId None; manufacturer id PEN Source form: Oph Sol; strength: 2% Recorded listing: General benefit Source prices (unrounded): $0.9500; ministry $0.9500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02009277 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13857
Interchangeable products
Opticrom · DIN 02230621 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02009277
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Opticrom · DIN 02230621 · 2% · Oph Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-10 — choose a marketed DIN from the same-category list.Discontinued 2019-01-10 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-01-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-01-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Opticrom · DIN 02230621 Manufacturer: Allergan Inc.; listing date 1998-02-17 Health Canada: Cancelled post market since 2019-01-10 · brand OPTICROM · ATC S01GX01 CROMOGLICIC ACID · form Solution · route Ophthalmic · ingredients CROMOLYN SODIUM 2 %/W/V · company Allergan inc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Opticrom: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49797 · Verify on the e-Formulary ↗ (DIN 02230621)

Source record
DIN 02230621: Opticrom Raw flags: notABenefit=Y, sec3=Y Item: 523600019; group id 640; item number 1613; lccId None; manufacturer id ALL Source form: Oph Sol; strength: 2% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230621 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=49797
Interchangeable products
Cromolyn Eye Drops · DIN 02009277 · $0.9500
Shortage status: discontinued (2021-02-24, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230621
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-01-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

KETOTIFEN

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.25mg/mL · Oph Sol-5mL Pk

OLOPATADINE HCL

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.2%, 0.1% · Oph Sol-2.5mL Pk, Oph Sol-5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

DICLOFENAC SODIUM

· 6 products · General benefit · strengths: 0.1% · Oph Sol

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

AFLIBERCEPT

· 6 products · Limited Use, codes 729, 730, 731 (4), Limited Use, codes 694, 695 (2) · strengths: 2mg/0.05mL, 8mg/0.07mL · Inj Sol-0.05mL Pref Syr (Preservative-Free), Inj Sol-0.07mL Pref Syr, Inj Sol-0.07mL Vial Pk, Sol for Intravitreal Inj-0.05mL Vial Pk

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS CROMOLYN EYE DROPS (cromolyn sodium ophthalmic solution) is indicated in the prevention of the signs and symptoms of seasonal allergic conjunctivitis (itching, tearing, congestion, etc.) . 1.1 Pediatrics Pediatrics (from 5 to 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of CROMOLYN EYE DROPS in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use . (Safety and efficacy in children under 5 years of age have not been established.) See 4 DOSAGE AND ADMINISTRATION. 1.2 Geriatrics Geriatrics (over 65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use . https://pdf.hres.ca/dpd_pm/00063259.PDF PM date: September 14, 2021 Source product: CROMOLYN EYE DROPS; DIN 02009277; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Opticrom · DIN 02230621 Shortage status: discontinued (2021-02-24, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230621

Check this DIN again

Other review policies

For Opticrom: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026